Lucy Scientific Discovery, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OTC.Pink
Lucy Scientific Discovery Inc. will be delisted from the Nasdaq Capital Market effective July 1, 2024, and will begin trading on the OTC Markets Group platform.
OTC.Pink
Lucy Scientific Discovery Inc. is facing potential delisting from Nasdaq due to non-compliance with filing and stockholders' equity rules, with a hearing scheduled for June 25, 2024.
OTC.Pink
8-K: Lucy Scientific Discovery Faces Nasdaq Delisting After Failing to Meet Minimum Equity Requirements
Lucy Scientific Discovery Inc. is facing delisting from the Nasdaq Capital Market due to insufficient stockholders' equity, and is appealing the decision.
OTC.Pink
Scott Reeves resigned from the Board of Directors of Lucy Scientific Discovery Inc. effective immediately on April 17, 2024.
OTC.Pink
Lucy Scientific Discovery, Inc. has terminated its amalgamation agreement with Bluesky Biologicals Inc. due to the failure of Bluesky to provide timely audited financial statements.
OTC.Pink
Lucy Scientific Discovery enacted a 1-for-10 reverse stock split to regain Nasdaq compliance and announced the expiration of its Chief Scientific Officer's contract.
OTC.Pink
Lucy Scientific Discovery, Inc. has received a delisting notice from Nasdaq due to insufficient stockholders' equity, and is also working to regain compliance with minimum bid price rules.